Genflow Biosciences Plc to Present Live at the Virtual Life Science Investor Forum March 7th
March 05 2024 - 9:28AM
UK Regulatory
LONDON, March 05, 2024 (GLOBE NEWSWIRE) -- Genflow
Biosciences Plc (LSE:GENF) (OTCQB:GENFF), an emerging
leader in the field of longevity research developing therapeutics
that can potentially halt or slow the ageing process, today
announces that Dr. Eric Leire Chief Executive Officer, will
present live at the virtual Life Science Investor Forum, hosted by
VirtualInvestorConferences.com, on March 7, 2024.
DATE: March 7, 2024
TIME: 10:00 AM ET
LINK: https://bit.ly/3OM3m93
Available for 1x1 meetings: March 8, 11 & 12, 2024 (GMT+1)
This will be a live, interactive online event where investors
are invited to ask Dr. Leire questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that online investors pre-register and run the
online system check to expedite participation and receive event
updates.
Learn more about the event at
www.virtualinvestorconferences.com.
Recent Genflow Highlights
- Genflow was awarded 2.89 million
Euros in two new grants that will broaden its research pipeline and
expand the size of its therapeutic markets over the next three
years. (Please refer to press release here.)
- Genflow to undertake key
Investigational New Drug (IND)-enabling development activities that
will help define the pharmacological and toxicological properties
of its lead drug candidate, GF-1002, and its potential benefits for
NASH patients.
- Initial site selection and QMS
framework for clinical readiness, expected by the end of 2025 for
its NASH program.
About Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Ltd. (LSE:GENF)
(OTCQB:GENFF), a biotechnology company headquartered in the UK with
R&D facilities in Belgium, is pioneering gene therapies to
decelerate the aging process, with the goal of promoting longer and
healthier lives while mitigating the financial, emotional, and
social impacts of a fast-growing aging global population. Genflow
Bioscienceās lead compound, GF-1002, works through the delivery of
a centenarian variant of the SIRT6 gene which has yielded promising
preclinical results. Scheduled to begin in 2025, Genflow
Biosciences' upcoming clinical trial aims to explore the potential
benefits of GF-1002 in treating non-alcoholic steatohepatitis
(NASH), the most prevalent chronic liver disease for which there is
no effective treatments. Please visit genflowbiosciences.com and
follow the Company on LinkedIn and Twitter/X.
About Virtual Investor ConferencesĀ®
Virtual Investor Conferences (VIC) is the leading proprietary
investor conference series that provides an interactive forum for
publicly traded companies to seamlessly present directly to
investors.
Providing a real-time investor engagement solution, VIC is
specifically designed to offer companies more efficient investor
access. Replicating the components of an on-site investor
conference, VIC offers companies enhanced capabilities to connect
with investors, schedule targeted one-on-one meetings and enhance
their presentations with dynamic video content. Accelerating the
next level of investor engagement, Virtual Investor Conferences
delivers leading investor communications to a global network of
retail and institutional investors.
CONTACTS:
Harbor Access
Jonathan Paterson
Investor Relations
+1 475 477 9401
Jonathan.Paterson@harbor-access.com
Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Nov 2024 to Dec 2024
Genflow Biosciences (LSE:GENF)
Historical Stock Chart
From Dec 2023 to Dec 2024